{"doi":"10.1371/journal.pone.0236000","title":"REV-ERB agonism improves liver pathology in a mouse model of NASH","abstract":"Non-alcoholic fatty liver disease (NAFLD) affects a significant number of people worldwide and currently there are no pharmacological treatments. NAFLD often presents with obesity, insulin resistance, and in some cases cardiovascular diseases. There is a clear need for treatment options to alleviate this disease since it often progresses to much more the much more severe non-alcoholic steatohepatitis (NASH). The REV-ERB nuclear receptor is a transcriptional repressor that regulates physiological processes involved in the development of NAFLD including lipogenesis and inflammation. We hypothesized that pharmacologically activating REV-ERB would suppress the progression of fatty liver in a mouse model of NASH. Using REV-ERB agonist SR9009 in a mouse NASH model, we demonstrate the beneficial effects of REV-ERB activation that led to an overall improvement of hepatic health by suppressing hepatic fibrosis and inflammatory response.","journal":"PLoS ONE","year":2020,"id":98718,"datarank":0.9177670312043826,"base_score":3.4965075614664802,"endowment":3.4965075614664802,"self_citation_contribution":0.5244761342199721,"citation_network_contribution":0.39329089698441055,"self_endowment_contribution":0.5244761342199721,"citer_contribution":0.39329089698441055,"corpus_percentile":null,"corpus_rank":null,"citation_count":32,"citer_count":28,"citers_with_citation_signal":22,"citers_with_endowment":22,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9524,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":487616,"name":"Gonzalo Bedia‐Diaz","orcid":null,"position":1,"is_corresponding":false},{"id":373275,"name":"Bahaa Elgendy","orcid":"0000-0003-4800-7976","position":2,"is_corresponding":false},{"id":373274,"name":"Thomas P. Burris","orcid":"0000-0003-2922-4449","position":3,"is_corresponding":false},{"id":476946,"name":"Kristine Griffett","orcid":"0000-0002-6747-2518","position":0,"is_corresponding":true}],"reference_count":26,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-18T22:36:58.511143Z","pmid":"33002003","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}